Brain Metabolism: Psilocybin, MDE, & Meth (Gouzoulis-Mayfrank et al., 1999) скачать в хорошем качестве

Brain Metabolism: Psilocybin, MDE, & Meth (Gouzoulis-Mayfrank et al., 1999)

I. Study Overview Researchers investigated the metabolic effects of three drugs. The study used FDG-PET scans on thirty-two healthy volunteers. Substances included psilocybin, MDE, and d-methamphetamine. The design was double-blind and placebo-controlled. Subjects performed word tasks to test cognitive activation. II. Psilocybin Metabolic Findings Psilocybin increased metabolism in the right anterior cingulate. It also increased activity in the right frontal operculum. Significant hypometabolism was observed in the thalamus. This pattern indicates a right hemispheric dominance. The findings align with a hyperfrontal metabolic pattern. III. Methamphetamine & MDE Effects Methamphetamine caused distinct cerebellar hypermetabolism. Researchers observed widespread cortical hypometabolism. This decrease was notable in frontal, parietal, and temporal areas. MDE effects were intermediate between psilocybin and meth. MDE showed cortical hypometabolism but some cingulate activity. IV. Cognitive Task Performance Subjects performed a word association task during the scans. Psilocybin blocked the expected activation of frontal regions. Participants found the task very difficult under psilocybin. Methamphetamine subjects reported the task was easy. MDE subjects also found the cognitive load manageable. V. Clinical Model Implications Hallucinogenic states may serve as models for acute psychosis. Acute states may involve frontal hyperactivity, unlike chronic ones. Chronic schizophrenia is often linked to hypofrontality. Psilocybin impairs focused activation despite general overactivity. This helps explain attentional deficits in psychotic states. VI. Additional Resource Support See NourishED RFI's NotebookLM Resource Support Page. https://notebooklm.google.com/noteboo... VII. Source Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O., Arning, C., Thelen, B., Spitzer, M., Kovar, K. A., Hermle, L., Büll, U., & Sass, H. (1999). Neurometabolic Effects of Psilocybin, 3,4 methylenedioxyethylamphetamine (MDE) & d-methamphetamine in Healthy Volunteers: A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology, 20(6), 565–581. #neuroscience #psilocybin #psychopharmacology #brainimaging #PETscan #mentalhealth #schizophrenia #5ht2a #psychedelicscience #psychedelicresearch ‪@Psychopharmacologyinstitute‬ ‪@ThePsychedelicScientist‬ ‪@AM_Fouda‬ ‪@SpeedPharmacology‬ ‪@neipsychopharm‬ ‪@ThePsychedelicScientist‬ ‪@naropaallianceforpsychedel7015‬ ‪@psychedelicsupport‬ ‪@PsychedelicsToday‬